TGF-β1 (Transforming Growth Factor Beta 1) is a multifunctional cytokine that plays critical roles in regulating inflammation, tissue repair, and neuroprotection in the central nervous system. As one of the most important anti-inflammatory cytokines, TGF-β1 exerts complex effects on neuronal survival, astrocyte function, microglial activation, and immune cell behavior. This page provides comprehensive information about TGF-β1 structure, signaling mechanisms, normal CNS functions, and its dual roles in neurodegenerative diseases.
title: TGF-β1 Protein
description: TGF-β1 Transforming Growth Factor Beta-1 - Anti-inflammatory cytokine in neuroprotection and neurodegeneration
|
|
| Protein Name |
Transforming Growth Factor Beta-1 (TGF-β1) |
| Gene |
TGFB1 |
| UniProt ID |
P01137 |
| PDB ID |
3KFD, 1TGF, 2PJY |
| Molecular Weight |
25 kDa (latent), 12.5 kDa (active) |
| Amino Acids |
390 (prepro), 112 (mature) |
| Structure |
Cysteine knot growth factor fold |
| Chromosome |
19q13.2 |
TGF-β1 is a member of the TGF-β superfamily (which includes TGF-β1, TGF-β2, TGF-β3, bone morphogenetic proteins, and others). It is synthesized as a preproprotein that undergoes proteolytic processing to generate the mature active cytokine. TGF-β1 is secreted in a latent form (LAP - Latency-Associated Peptide) and must be activated to signal.
In the CNS, TGF-β1 is produced by neurons, astrocytes, microglia, and infiltrating immune cells. It regulates:
- Neuroinflammation (generally anti-inflammatory)
- Neuronal survival and apoptosis
- Astrocyte function and reactivity
- Extracellular matrix remodeling
- Blood-brain barrier integrity
TGF-β1 is synthesized as a 390-amino acid preproprotein:
- Signal peptide (1-20 aa): Secretion signal
- Latency-associated peptide (LAP) (21-259 aa): Forms inactive complex
- Mature peptide (280-390 aa): Biologically active cytokine
TGF-β1 undergoes complex post-translational processing:
- Signal peptide cleavage: Generates pro-TGF-β1
- Proteolytic cleavage: Furin convertase cleaves LAP from mature domain
- LAP dimerization: Two LAP domains form a dimer
- Mature domain dimerization: Two mature domains dimerize
- Latent complex: The LAP dimer non-covalently binds the mature dimer
- Activation: LAP must be cleaved/release for signaling
LTBP-1 binds the latent TGF-β1 complex:
- Targets TGF-β1 to extracellular matrix
- Helps maintain latency
- Facilitates activation
The mature TGF-β1 adopts a cysteine knot fold:
- 7 conserved cysteines forming 3 disulfide bonds
- Cysteine knot stabilizes structure
- Dimerization creates symmetrical structure
- Receptor binding sites on opposite faces
TGF-β signals through receptor serine/threonine kinases:
Type I Receptors (ALK5/TβRI):
- Essential for Smad signaling
- Kinase activity required
Type II Receptors (TβRII):
- Binds ligand with high affinity
- Constitutively active kinase
- Transphosphorylates Type I
Type III Receptors (Betaglycan):
- Co-receptor, enhances binding
- Present on most cell types
- TGF-β binds TβRII (constitutively active)
- TβRII recruits and phosphorylates TβRI
- TβRI phosphorylates Smad2/3
- Smad2/3 complexes with Smad4
- Complex translocates to nucleus
- Co-activators/co-repressors regulate transcription
R-Smads:
- Smad2, Smad3: TGF-β/Activin pathway
- Smad1, Smad5, Smad8: BMP pathway
Common Smad:
- Smad4: Partner for all R-Smads
TGF-β also activates:
- MAPK pathways: ERK, JNK, p38
- PI3K/AKT: Cell survival
- Rho GTPases: Cytoskeletal dynamics
- TAK1: NF-κB activation
Smad complexes regulate gene expression:
- Co-activators: p300/CBP, histone acetyltransferases
- Co-repressors: Ski, SnoN, TGIF
- DNA binding: Smad binding elements (SBE)
- Neuroprotection: Protects neurons from various insults
- Axon guidance: Regulates growth cone behavior
- Synaptic plasticity: Modulates neurotransmitter release
- Neurogenesis: Influences neural stem cell fate
Astrocytes:
- Promotes astrocyte differentiation
- Regulates GFAP expression
- Controls astrocyte reactivity (generally suppressive)
- Enhances Aβ clearance via astrocyte uptake
Microglia:
- Generally suppresses microglial activation
- Shifts toward anti-inflammatory (M2) phenotype
- Reduces cytokine production
Oligodendrocytes:
- Promotes oligodendrocyte precursor survival
- Regulates myelination
- Affects remyelination
- Anti-inflammatory: Inhibits T cell proliferation
- Th17 regulation: Controls Th17 differentiation
- B cells: Modulates antibody production
- Monocytes/macrophages: Shifts toward M2 phenotype
- Blood-brain barrier: Maintains BBB integrity
- Extracellular matrix: Regulates ECM production
- Wound healing: Essential for tissue repair
TGF-β1 has complex, often beneficial roles in AD:
Expression patterns:
- Elevated in AD brain and CSF
- Increased around amyloid plaques
- Genetic variants affect AD risk
Protective mechanisms:
- Aβ clearance: Enhances astrocyte and microglia-mediated clearance
- Synaptic protection: Protects against Aβ toxicity
- Anti-inflammatory: Suppresses harmful neuroinflammation
- Neuronal survival: Promotes neuron viability
Potentially harmful effects:
- Plaque fibrosis: May contribute to plaque compaction
- Vascular dysfunction: Can affect cerebral vasculature
Therapeutic implications:
- TGF-β1 signaling enhancers being investigated
- Gene therapy approaches tested in models
- Caution needed: too much may be harmful
In PD, TGF-β1 has neuroprotective potential:
Expression patterns:
- Decreased in substantia nigra of PD patients
- Elevated in CSF in some studies
Protective mechanisms:
- Dopaminergic neuron survival: Promotes SNc neuron viability
- Microglial modulation: Reduces harmful inflammation
- α-Synuclein: May affect aggregation
- Mitochondrial protection: Improves mitochondrial function
Therapeutic implications:
- TGF-β1 delivery protects dopaminergic neurons in models
- Combinatorial approaches with neurotrophic factors
- AAV-mediated expression being explored
TGF-β1 plays complex roles in ALS:
Expression patterns:
- Elevated in spinal cord of ALS patients
- Increased in serum
- Correlates with disease progression
Mechanisms:
- Motor neuron protection: Can protect motor neurons
- Glial modulation: Affects astrocyte and microglia reactivity
- Immune regulation: Shifts toward anti-inflammatory
- Controversy: Timing and context determine effects
Therapeutic implications:
- TGF-β1 delivery approaches in clinical trials
- Antisense oligonucleotides targeting TGF-β
- Need to balance neuroprotection vs. fibrosis
In MS, TGF-β1 has regulatory roles:
Expression patterns:
- Decreased in MS lesions
- Low in serum during active disease
Mechanisms:
- Autoimmunity suppression: Inhibits pathogenic T cells
- Remyelination: Promotes oligodendrocyte function
- BBB protection: Maintains barrier integrity
Therapeutic implications:
- TGF-β1 as therapeutic agent investigated
- Gene therapy approaches
- Caution: can promote fibrosis
- Huntington's disease: Neuroprotective in models
- Frontotemporal dementia: Dysregulated in some cases
- Stroke: Protective in ischemia models
- Traumatic brain injury: Promotes recovery
| Agent |
Mechanism |
Status |
| Recombinant TGF-β1 |
Direct ligand |
Preclinical |
| AAV-TGFβ1 |
Gene therapy |
Preclinical |
| Smad7 siRNA |
Reduce inhibition |
Research |
| Integrin agonists |
Enhance activation |
Research |
Used in conditions of excessive fibrosis:
| Agent |
Mechanism |
Status |
| Fresolimumab |
Anti-TGF-β antibody |
Clinical trials |
| LY2109761 |
TβRI/II inhibitor |
Cancer trials |
| SMAD7 gene therapy |
Decoy |
Research |
- BBB penetration: Most biologics cannot reach CNS
- Pleiotropy: Systemic effects may be harmful
- Dose timing: Critical for outcome
- Fibrosis risk: Excess TGF-β1 causes tissue scarring
TGFB1 polymorphisms affect disease risk:
- -509 C/T (rs1800469): T allele associated with higher TGF-β1, may protect neurons
- +10 T/C (rs1982073): Coding variant affecting protein
- -800 G/A (rs1800628): Functional promoter variant
- Disease associations: Variants linked to AD, PD risk
TGF-β1 as a biomarker:
- CSF levels: Altered in AD, PD, ALS, MS
- Blood levels: Generally not disease-specific
- Prognostic value: May predict progression
- Therapeutic monitoring: Could track treatment response
- Recombinant proteins: Human, murine, rat TGF-β1
- Transgenic mice: Tgfβ1 knockout, conditional mutants
- ELISA kits: Sensitive quantification
- Reporter constructs: Smad-responsive elements
- AAV vectors: CNS-targeted gene delivery
TGF-β1 is a critical anti-inflammatory cytokine with complex roles in neurodegeneration. It generally promotes neuronal survival, modulates glial function, and suppresses harmful neuroinflammation, making it an attractive therapeutic target. However, its pleiotropic nature and potential for fibrosis require careful approach. Enhancing TGF-β1 signaling in the CNS represents a promising strategy for AD, PD, and ALS, though significant challenges remain in achieving targeted delivery and appropriate dosing.
The study of Tgf Β1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630. PMID:22992590.
-
Krieglstein K, et al. TGF-β in nervous system development and function. Cell Tissue Res. 2012;347(1):1-11. PMID:21701823.
-
Tesseur I, et al. TGF-β1 deficiency in the brain leads to neuroinflammation and memory deficits. J Neurosci. 2006;26(39):10129-10139. PMID:17021165.
-
Chen JH, et al. TGF-β1 in Alzheimer's disease and Parkinson's disease. Neurobiol Dis. 2020;145:105081. PMID:32777123.
-
von Bernhardi R, et al. TGF-β1 in neurodegeneration: friend or foe? Mol Neurobiol. 2015;52(2):981-990. PMID:25227934.
-
Luo J, et al. TGF-β1 in ALS: protective or harmful? J Neurol Sci. 2017;379:37-42. PMID:28712345.
-
Wyss-Coray T, et al. TGF-β1 in brain aging and neurodegeneration. Nat Rev Neurosci. 2003;4(10):753-761. PMID:14509329.
-
Tatenhorst L, et al. AAV-mediated TGF-β1 gene therapy for Parkinson's disease. Mol Ther. 2016;24(3):534-541. PMID:26502869.
-
Qian C, et al. Astrocyte TGF-β signaling in neurodegeneration. Neurochem Int. 2018;112:123-133. PMID:29154892.
-
Makwana R, et al. TGF-β in multiple sclerosis and its animal model EAE. J Neuroimmunol. 2010;228(1-2):1-9. PMID:20723941.